Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Oct;38(10 Suppl):S569-73.
doi: 10.1097/CCM.0b013e3181f1ff1d.

Mesenchymal stem cells for acute lung injury: preclinical evidence

Michael A Matthay  1 , Arnaud Goolaerts, James P Howard, Jae Woo Lee
Affiliations
Review

Mesenchymal stem cells for acute lung injury: preclinical evidence

Michael A Matthay et al. Crit Care Med. 2010 Oct.

Abstract

Several experimental studies have suggested that mesenchymal stem cells may have value for the treatment of clinical disorders, including myocardial infarction, diabetes, acute renal failure, sepsis, and acute lung injury. In preclinical studies, mesenchymal stem cells have been effective in reducing lung injury from endotoxin, live bacteria, bleomycin, and hyperoxia. In some studies, the cultured medium from mesenchymal stem cells has been as effective as the mesenchymal stem cells themselves. Several paracrine mediators that can mediate the effect of mesenchymal stem cells have been identified, including interleukin-10, interleukin-1ra, keratinocyte growth factor, and prostaglandin E2. Further preclinical studies are needed, as is planning for clinical trials for acute lung injury.

PubMed Disclaimer

Conflict of interest statement

The authors have not disclosed any potential conflicts of interest.

Figures

Figure 1
Figure 1
Effect of human mesenchymal stem cells or their conditioned medium on lung endothelial permeability to protein and wet-to-dry (W/D) ratio in the ex vivo perfused human lung injured with Escherichia coli endotoxin. Instillation of mesenchymal stem cells (MSCs) or their conditioned medium (CM) into the E. coli endotoxin (0.1 mg/kg) injured right middle lobe 1 hr after injury restored lung endothelial permeability to protein (A) and W/D ratio (B) to control values. Data are expressed as mean % endothelial permeability or W/D ratio ± SD; n = 4 to 5 lungs. (A) *p < .0001 vs. control lobe. †p < .0011 vs. lipopolysaccharide (LPS) (0.1 mg/kg) injured lobe for lung endothelial permeability. (B) *p < .0014 vs. control lobe. †p < .005 vs. LPS (0.1 mg/kg) injured lobe for the W/D ratio by analysis of variance (Bonferroni). Reprinted with permission from Aslam et al (26).
See this image and copyright information in PMC

References

    1. Brower RG, Morris A, MacIntryre N, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342:1301–1308. - PubMed
    1. Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354:2564–2575. - PubMed
    1. Calfee CS, Matthay MA. Nonventilatory treatments for acute lung injury and ARDS. Chest. 2007;131:913–920. - PMC - PubMed
    1. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353:1685–1693. - PubMed
    1. Cepkova M, Matthay MA. Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J Intensive Care Med. 2006;21:119–143. - PMC - PubMed

Publication types